1 min read Genexine appoints Intralink to drive development of business in Japan 17 June 2013 See more posts on Medtech & Life Sciences Seoul, South Korea — Korean biotech company Genexine, which specialises in new generation therapeutic vaccine technologies, has appointed Intralink to drive the development of its business in Japan. Share: Share on Facebook Share on Twitter Share on LinkedIn Share on Email Sign up For our news and blog posts Newsletter signup First name Surname Email Your personal data is safe with us. See our Privacy Notice.